LONDON, UK: Syncona Ltd it has committed £15 million in an oversubscribed £75.5 million Series B financing in OMass Therapeutics, a biotechnology company that identifies medicines against highly validated target ecosystems. Syncona was a co-investor in this financing round, which was led by new investors GV, Northpond and Sanofi Ventures. Existing investors Oxford Science Enterprises…